Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2025)

Historic Net Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 212.1%.

  • Monte Rosa Therapeutics' Net Margin rose 467900.0% to 212.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.52%, marking a year-over-year increase of 8088900.0%. This contributed to the annual value of 96.18% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Net Margin is 212.1%, which was up 467900.0% from 53.01% recorded in Q2 2025.
  • Monte Rosa Therapeutics' Net Margin's 5-year high stood at 55.2% during Q1 2025, with a 5-year trough of 3006.11% in Q1 2024.